GlassScriptPhysician profile
Shaji P Daniel
NPI 1639384548
$989.51
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $17.40 · 2021: $67.20 · 2022: $50.50 · 2023: $375 · 2024: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.45 |
| Education | $133.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $316.78 | 2023-2024 | Renal - Pd |
| Novo Nordisk INC | $133.72 | 2024 | Ozempic, Wegovy |
| Calliditas Therapeutics US INC. | $125.00 | 2023 | Tarpeyo |
| Horizon Therapeutics Plc | $124.91 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $121.15 | 2019-2022 | |
| Vifor Pharma, INC. | $48.70 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $35.19 | 2019-2020 | |
| Eurofins Viracor, LLC | $33.35 | 2021 | |
| Genzyme Corporation | $18.72 | 2019 | |
| Glaxosmithkline, LLC. | $16.76 | 2024 | Benlysta |
| Alnylam Pharmaceuticals INC. | $15.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaji Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.